Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2021-05-18 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2021-05-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, Ryaltris®-AZ, by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release with detailed product information, pricing, and market context. There are no financial statements, regulatory filings, or management discussions of financial results. The content is promotional and informational about a product launch rather than a financial report, regulatory filing, or corporate governance document. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories. Given the nature and length of the document, the most appropriate classification is Regulatory Filings (RNS).
2021-05-03 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) disclosing a corporate transaction under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details Glenmark Pharmaceuticals Limited entering into an agreement to become a partner in a new LLP entity, including specifics about the target entity, nature of the transaction, consideration, and other regulatory disclosures. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a capital investment/partnership transaction, which fits the category of Capital/Financing Update (CAP). The document length is about 4808 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2021-04-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the approval of Glenmark's Ryaltris nasal spray in Europe. It is addressed to stock exchanges and includes a media release about a product launch and regulatory approval. There are no financial statements, no detailed financial performance data, no management discussion of financial results, nor any regulatory filing forms or certifications. The document is a corporate announcement about a product approval and commercialization update, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate news. The document length is about 5309 characters, which is relatively short and consistent with a press release rather than a full report. Therefore, the classification is RNS with high confidence.
2021-04-26 English
Annual Disclosure
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a regulatory disclosure. It states that Glenmark Pharmaceuticals Limited is not classified as a Large Corporate under a specific SEBI circular and therefore is not required to submit the related disclosure. The document is short (1528 characters), formal, and serves as a regulatory compliance statement rather than a financial report or detailed filing. It does not contain financial data, management discussion, or any report content. It is essentially a regulatory announcement or compliance confirmation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-04-26 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the filing of a draft red herring prospectus for an Initial Public Offering (IPO) of Glenmark Life Sciences Limited, a subsidiary of Glenmark Pharmaceuticals Limited. It mentions the approval by the board of directors for the offer for sale of shares and states that the IPO is subject to market conditions and approvals. The document is an announcement regarding a capital raising activity (IPO) and not a full financial report or detailed prospectus itself. The length is short (2246 characters), and it serves as a notification of a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-04-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.